-Today I talk about Madrigal Pharmaceuticals and their recent Phase 2 data announcement of MGL-3196 effects in HeFH patients -The stock has good long-term potential, their drug shows a profound effect on blood lipids and cholesterol -Look out for final NASH biopsy data in May-2018 https://breakingbiotech.com/2018/03/06/madrigal-pharma-shows-positive-phase-2-data-in-hefh/ https://breakingbiotech.com/2018/01/16/madrigals-nash-candidate-a-winner/